# **1** Impact of Vaccination Rates, Pre-Pandemic Life Expectancy, Economic

# 2 Status and Age on COVID-19 Excess Mortality Across United States

- 3 Olga Matveeva<sup>1\*</sup>; Aleksey Y. Ogurtsov<sup>2</sup>; and Svetlana A. Shabalina<sup>2\*</sup>
- <sup>4</sup> <sup>1</sup>Sendai Viralytics LLC, Acton, MA 01720, USA.
- <sup>5</sup> <sup>2</sup>National Center for Biotechnology Information, National Library of Medicine, National Institutes of
- 6 Health, Bethesda, MD 20894-6075, USA.
- 7 \*Corresponding authors: <u>olga.matveeva@gmail.com</u>; <u>shabalin@ncbi.nlm.nih.gov</u>

### 8 Abstract

Aim: This study investigates factors influencing pandemic mortality rates across U.S. states during
 different waves of SARS-CoV-2 infection from February 2020 to April 2023, given that over one
 million people died from COVID-19 in the country.

Methods: We performed statistical analyses and used linear regression models to estimate age-adjusted and unadjusted excess mortality as functions of life expectancy, vaccination rates, and GDP per capita in U.S. states.

**Results and Discussion:** States with lower life expectancy and lower GDP per capita experienced 15 significantly higher mortality rates during the pandemic, underscoring the critical role of underlying 16 health conditions and healthcare infrastructure, as reflected in these factors. When categorizing states 17 18 by vaccination rates, significant differences in GDP per capita and pre-pandemic life expectancy emerged between states with lower and higher vaccination rates, likely explaining mortality disparities 19 before mass vaccination. During the Delta and Omicron BA.1 waves, when vaccines were widely 20 available, the mortality gap widened, and states with lower vaccination rates experienced nearly double 21 22 the mortality compared to states with higher vaccination rates (Odds Ratio 1.8, 95% CI 1.7-1.9, p < p0.01). This disparity disappeared during the later Omicron variants, likely because the levels of 23 combined immunity from vaccination and widespread infection across state populations became 24 comparable. We showed that vaccination rates were the only significant factor influencing age-adjusted 25 mortality, highlighting the substantial impact of age-specific demographics on both life expectancy and 26 GDP across states. 27

**Conclusion:** The study underscores the critical role of high vaccination rates in reducing excess deaths across all states, regardless of economic status. Vaccination rates proved more decisive than GDP per capita in reducing excess deaths. Additionally, states with lower pre-pandemic life expectancy faced greater challenges, reflecting the combined effects of healthcare quality, demographic variations, and social determinants of health. These findings call for comprehensive public health strategies that address both immediate interventions, like vaccination, and long-term improvements in healthcare infrastructure and social conditions.

## 35 Keywords: Vaccination Rate, Life expectancy, Pandemic Excess Mortality, Age-specific

#### 36 Adjustment, COVID-19, Gross Domestic Product

## 38 Introduction

In May 2023, the U.S. Centers for Disease Control and Prevention (CDC) and the World Health 39 Organization (WHO) officially declared the end of the COVID-19 pandemic as a public health 40 emergency. However, despite the decline in COVID-19 infections, persistent morbidity, and mortality, 41 coupled with the looming threat of future significant outbreaks, necessitate a thorough examination of 42 the effectiveness of past pandemic control strategies. Numerous studies confirm the effectiveness of 43 COVID-19 vaccination in reducing deaths across US states (1-4). State-level analyses reveal that high 44 vaccination rates are associated with a lower risk of hospitalization due to COVID-19 (4) and fewer 45 overall hospitalizations (2) estimated that vaccination prevented roughly 5,000 hospitalizations and 46 saved approximately 700 lives per 100,000 people in the US (5). 47

48 A sustained reduction in mortality rates, along with an increase in vaccination coverage, has been observed across states throughout the Alpha, Delta, and Omicron waves of the pandemic (6). 49 Notably, a 10% increase in vaccination coverage was linked to an 8% decrease in mortality and a 7% 50 decrease in COVID-19 cases (7). It has been observed that the 10 states with the highest vaccination 51 rates had all-cause mortality rates comparable to, or even lower than, some European countries during 52 the combined Delta and Omicron waves (3). Thus, research suggests significant geographical 53 disparities in vaccination coverage across the US, with areas of low vaccination identified as "cold 54 spots" (8). This unequal access to vaccination may be linked to variations in healthcare capacity. 55

The research team led by Bollyky et al. (9) conducted a comprehensive analysis of the factors influencing the impact of the COVID-19 pandemic in the US. They found that socioeconomic factors such as low poverty levels, higher education, and trust in institutions were linked to lower death rates. Conversely, states with higher percentages of minority populations experienced higher death rates.

Access to quality healthcare was shown to reduce deaths and infections, while increased public health
 spending and personnel did not significantly affect outcomes.

While the Bollyky et al. (2023) study (9) found no direct correlation between state Gross 62 Domestic Product (GDP) per capita and pandemic age-adjusted mortality within the US, lower GDP is 63 often associated with challenges in healthcare infrastructure, resource availability, and social support 64 systems. These limitations may indirectly contribute to higher overall pandemic mortality rates. 65 Globally, studies have shown a link between low excess mortality, high vaccination rates, and high 66 GDP (10-12). However, the complex interplay of these factors and the mechanisms by which they 67 affected pandemic mortality in the US context remains understudied. Our comprehensive analysis 68 across all 50 states addresses this gap by examining the relationship between age-adjusted and 69 unadjusted pandemic mortality estimates, vaccination rates, and socioeconomic factors (including GDP 70 per capita and pre-pandemic life expectancy). 71

For this analysis, we chose to assess excess mortality because it provides a more comprehensive measure of the overall impact of the pandemic than reported COVID-19 deaths alone. It accounts for both direct COVID-19 fatalities and indirect effects such as disruptions in healthcare systems, delayed medical treatments, and other socioeconomic impacts.

We also analyzed the relationship between pre-pandemic life expectancy and pandemic mortality. So far, we have been unable to find published studies that directly investigate this relationship and the mechanisms underlying it. The main research focus of published research is on addressing the question of how the pandemic has shortened life expectancy in different jurisdictions internationally (13) and within the USA (14). However, accounting for state-specific pre-pandemic life expectancy when analyzing pandemic mortality is important because life expectancy captures and integrates the impact of underlying health conditions, healthcare quality, and demographic differences, such as age

distribution, which influence vulnerability to pandemics. It also highlights differences in healthcare infrastructure and social determinants of health, such as income and access to care, which can exacerbate mortality rates.

86 This study takes statistical approaches by simultaneously considering many factors in 87 univariable and multivariable regression analysis along with partial correlation estimates.

By integrating both vaccination rates and economic indicators, this research seeks to shed light on the intricate dynamics influencing excess mortality, paving the way for more effective and targeted public health interventions. Furthermore, investigating the relationship between pandemic mortality and life expectancy across U.S. states can yield valuable insights into how the pandemic has disproportionately impacted different populations within the United States.

#### 93 Materials and Methods

#### 94 Life expectancy

Life expectancy at birth estimated for 2019 for US states was extracted from US Mortality Database
(15).

#### 97 Total pandemic age-adjusted and unadjusted pandemic mortality from the earlier published study

Age-adjusted and unadjusted COVID-19 pandemic mortality estimates for each U.S. state, spanning January 1, 2020, to July 31, 2022, were derived from a previously published study (9). In addition we also used excess mortality estimates (age-unadjusted) derived form CDC modelling as desribed below.

#### 102 Excess mortality derived from CDC modeling

103Data on excess mortality in the United States were also sourced from the US Centers for Disease104Control and Prevention (CDC) (16). We downloaded the file "National and State Estimates of Excess

105	Deaths" for our analysis. To ensure proper comparisons, we normalized the absolute values of excess
106	mortality for each specific period using the population size of each state obtained from the United States
107	Census Bureau's 2020 data (17). For this normalization process, we used the file "Annual Estimates of
108	the Resident Population for the United States, Regions, States, District of Columbia, and Puerto Rico:
109	April 1, 2020, to July 1, 2022."

110 CDC's method for calculating excess deaths involves a modeling approach that compares recent 111 mortality data to historical trends dating back to 2013 (18). This analysis aims to identify significant 112 increases in all-cause mortality.

#### 113 Vaccination dataset

Vaccination data for the United States was also procured from the US Centers for Disease 114 Control and Prevention (CDC) (19). We downloaded the file "COVID-19 Vaccinations in the United 115 States, Jurisdiction" and extracted data that were relevant to the dates October 2, 2021, and January 2, 116 2022, from the column "titled "Series Complete Pop Pct" and booster doses from the column titled 117 "Additional Doses Vax Pct". Information about the file is available in CDC (19). Additionally, we 118 included a dataset on the state's annual per capita gross domestic product (GDP) per capita for 2020 119 and 2021. We obtained this dataset from the Bureau of Economic Analysis (20), and used the file 120 121 "Annual GDP by State and Industry".

#### 122 Vaccination hesitancy

Data were obtained from Office of Assistant Secretary for Planning and Evaluation (ASPE) (21). The file titled "Predicted-Vaccine Hesitancy-by State, PUMA, and County" was used for the study.

126 Statistical analysis

127 The time intervals for analysis were classified as follows:

- I. Pre-Delta (February 1, 2020-June 30, 2021): This period represents the initial period of the pandemic
  before the emergence of the Delta variant.
- 130 II. Delta (July 1, 2021-January 31, 2022): The Delta variant was predominant, and mass vaccination
- 131 was already underway. The Delta-Omicron transition happened in December/January 2022.
- 132 III. Omicron BA.1 (February 1, 2022-March 30, 2022): The specific period corresponds to prevalence
- 133 of the first Omicron variant.
- IV. Post-Omicron BA.1 (April 1, 2022-April 1, 2023): This interval covered the period after the
  emergence of the first Omicron variant. Summary information for statistical analysis from the
  specified databases for the indicated time intervals was presented in Supplementary Table 1.
- All states were categorized based on real GDP per-capita in 2020 using the threshold that was
   chosen arbitrarily. States with GDP per-capita above \$65,000 were classified as higher-income, while
   those below \$65,000 were considered less affluent.
- Statistical analysis, including Pearson correlation analysis, linear regression fitting, and Odds
  Ratio calculations, was performed using Excel functions. In addition, we validated the results using the
  online tool (22).

### 143 **Results**

# 144 Complex interplay between pandemic mortality, life expectancy, GDP, and vaccination rates across 145 US States

To understand the impact of age on excess pandemic mortality across U.S. states, we analyzed the relationship between age-adjusted and unadjusted estimates. We correlated these estimates with each other, with pre-pandemic state-specific life expectancy and annual GDP per capita values. Interestingly, life expectancy correlates better with unadjusted mortality (Figure 1A) compared to age-

adjusted mortality (Figure 1B). This suggests that states with lower life expectancy experienced higher overall mortality during the pandemic, likely due to factors such as poorer healthcare infrastructure, higher prevalence of chronic conditions, and other socioeconomic differences. However, ageadjustment diminishes this effect. This finding highlights the importance of pre-pandemic health, as measured by life expectancy, in determining a state's vulnerability to excess mortality during a pandemic. Age-adjustment partially mitigates this effect, suggesting that older populations are a significant contributing factor.

While the two mortality estimates age-adjusted and unadjusted are correlated with each other,
this correlation is more pronounced for states with GDP per capita at or below \$65,000 (Figure1C).
This indicates that demographic factors play a substantial role in determining overall mortality in these
states.

Interestingly, the strong correlation (R=-0.89, p<0.05) between pandemic age-unadjusted mortality and pre-pandemic life expectancy persists even when controlling for other variables, including vaccination and GDP, with partial correlations ranging between -0.87 and -0.84, as shown in Figure 1A. However, the partial correlation between age-adjusted mortality and life expectancy disappears when we control for vaccination rate (Figure 1B). This finding underscores the significant role of vaccination in influencing pandemic mortality outcomes, suggesting that vaccination efforts can effectively mitigate the impact of pre-existing health vulnerabilities, as reflected by life expectancy.

Additionally, not surprisingly, we noticed that states with lower GDP have lower pre-pandemic life expectancy. However, this effect is noticeable only for states with GDP at or below \$65,000. Thus, the correlation between these variables is significant (p < 0.05) only for states within this subset (Figure 1D). The relationship disappears for higher income states. This suggests a diminishing effect of income on life expectancy beyond a certain GDP threshold (around \$65,000 per capita in this study). Perhaps

other factors besides just wealth become more important determinants of health outcomes in high-income states.

175 Similar to the life expectancy relationship, the link between lower pandemic mortality and higher GDP is only significant for lower-GDP states (with a GDP per capita at or below \$65,000), 176 suggesting that after reaching a certain threshold more economic resources doesn't necessarily translate 177 178 to a bigger reduction in pandemic deaths. Interestingly, there is a nuance in the relationships between GDP and pandemic mortality depending on age-consideration. Thus, within this lower-GDP subset, the 179 correlation with GDP is weaker for age-adjusted mortality compared to unadjusted mortality (refer to 180 Supplementary Figures 1A and 1B). This suggests that factors other than economic resources might 181 182 play a more significant role in affecting mortality rates when age structure of the population is considered. 183

#### 184 Visualizing COVID-19 mortality waves and vaccination progress

The relationship between mortality dynamics and the COVID-19 pandemic is highlighted by the successive waves of SARS-CoV-2 infections, driven by the emergence and dominance of distinct viral variants. Fatalities arise from both direct COVID-19 impact and broader effects. The interplay between the evolving viral genomes and host responses elucidates temporal patterns in morbidity and mortality observed across pandemic infection waves. Figure 2A visually depicts daily reported COVID-19 deaths, illustrating distinct waves of infection and periods dominated by specific variants. Supplementary Figure demonstrates the chronological dominance of these variants.

As a first step toward understanding pandemic disease dynamics and evaluating the effectiveness of vaccination efforts, excess mortality (non-adjusted for age) was calculated separately for the pre-Delta, Delta-Omicron BA.1, and post-Omicron BA.1 periods. These periods are marked with distinct colors in Figure 2A. In the next step of the analysis, we ranked the states according to their

vaccination rates and divided them into three categories, as shown in Figure 2B. The "fast" category 196 included states in which the vaccination coverage for residents reached 60% by October 2, 2021, and 197 198 70% by January 2, 2022. This category includes the states of Vermont, Connecticut, Maine, Rhode Island, Massachusetts, New Jersey, Maryland, and New York. The "slow" category includes states 199 200 where more than half of the residents remained unvaccinated as of October 2, 2021. This category 201 includes North Carolina, Montana, Indiana, Missouri, Oklahoma, South Carolina, Arkansas, Georgia, Louisiana, Tennessee, North Dakota, Mississippi, Alabama, Idaho, Wyoming, and West Virginia. The 202 remaining states were categorized as having an intermediate vaccination rate. 203

States with higher pre-pandemic life expectancy also tended to have higher vaccination rates during the pandemic. Two parameters are highly and significantly correlated with each other (R=0.66, p<0.05). This relationship may reflect underlying factors such as better healthcare infrastructure, public health policies, and health awareness that contribute to both higher life expectancy and greater vaccine uptake.

Finally, we integrated information pertaining to mortality and vaccination rates by calculating and illustrating the number of fatalities in each state based on its respective category and time intervals (Figure 2C).

# Pronounced differences in excess mortality among state categories throughout successive pandemic periods

#### 214 <u>States with higher vaccination rate tended to have lower mortality rates</u>

The interaction between excess mortality and vaccination rates throughout the pandemic were analyzed using data from different state categories across three distinct time periods. During the first pre-Delta period (time interval I lasted from January 1, 2020, to June 30, 2021), mass vaccination had

just begun, and thus, did not significantly prevent excess mortality. In the second period, combining 218 Delta and Omicron BA.1 infection waves (time interval II lasted from July1, 2021 to March 30, 2022), 219 vaccination became widespread, potentially playing a significant role in reducing excess mortality 220 rates. In the third period, after the Omicron BA.1 wave (time interval III lasted from April 1, 2022, to 221 April 30, 2023), the bulk of the population acquired immunity through direct COVID-19 infection, 222 223 vaccination, or hybrid immunity (a combination of both). As a result, the association between high vaccination rates and low mortality, if previously significant, may become weak or disappear 224 altogether. 225

We employed odds ratio analysis to compare the likelihood of death in one category of states 226 to another and to quantify the association between vaccination rates and mortality. The results of our 227 analysis, conducted over distinct periods, are consistent with our predictions, and are presented in 228 Figure 3. Initially, during the pre-Delta period, the differences between states with the slowest and 229 fastest vaccination rates were significant, but not very pronounced (OR=1.41, 95% CI 1.32–1.5, 230 231 p < 0.01), boxplots in Figure 3A illustrate this difference for state categories created according to vaccination rates. However, as widespread mass vaccination took place during the Delta period, the 232 233 disparities between states with the slowest and fastest vaccination rates became more prominent 234 (OR=1.8, 95% CI 1.66–1.92, p<0.01), as demonstrated in Figure 3B.

Importantly, no substantial differences in excess mortality were observed between state categories in the post-Omicron BA.1 period, when a significant proportion of the population across all states likely attained seroconversion through the combination of vaccination and prior COVID-19 infection (Figure 3C).

239 States with higher vaccination rates tend to have higher GDP per capita and longer life expectancies

In the previous subsection, we demonstrated that states with faster vaccination rates have lower 240 excess mortality, with the most pronounced effect observed during the period of the pandemic 241 242 dominated by the Delta and Omicron BA.1 variants. However, this reduction in mortality cannot be attributed solely to differences in vaccination rates. As shown in Figure 4, these states differ 243 significantly in GDP per capita (Figure 4A) and life expectancy (Figure 4B). States with higher 244 245 vaccination rates tend to have higher GDP and longer life expectancy, both of which are significantly negatively correlated with mortality. Therefore, the individual and combined contributions of these 246 factors in determining excess mortality should be considered, weighted, and studied both together and 247 independently. 248

#### 249 A complex interplay between vaccination and economic status of U.S. states

Fewer excess deaths happened in states with higher GDP per capita and higher vaccination rates. Figure 5 illustrates this effect for excess mortality during the combined Delta and Omicron BA.1 variant periods, while Supplementary Figure 3 shows this effect separately for the Delta and Omicron BA.1 variants. This result is not surprising, as states with higher incomes achieved faster vaccination rates, and the relationship between these factors is significant (R=0.4, p<0.05). Both lower vaccination rates and lower GDP drive higher mortality across states; however, there are nuances in these trends.

Among the states with GDP per capita at or below \$65,000, age-unadjusted excess mortality has a stronger negative correlation with state income compared to those with higher income (Figure 5A). Moreover, with the same level of low vaccination, states with GDP above \$65,000 have lower mortality compared to their less wealthy counterparts (Figure 5B). Two factors high vaccination rates and high income appear to have synergetic effects on lowing mortality across states. This synergy is also evident in multivariable regression analysis, where age unadjusted pandemic mortality is the

dependent variable while vaccination rate, and GDP are independent variables. Both parameters remain
 significant (Supplementary Table 2).

However, age adjustment for estimates of mortality changes the picture: the synergy of two parameters in defining excess mortality disappears. The same level of low vaccination corresponds to the same level of excess deaths, regardless of GDP (compare Supplementary Figure 4 A and Figure 4 B). Thus, a high vaccination rate is the most crucial factor in defining low age-adjusted excess mortality, overriding the impact of GDP.

#### 269 The importance and significance of mortality predictors changes troughtout the pandemic periods

Multivariable regression models indicated that life expectancy, vaccination coverage, and GDP 270 271 significantly influenced age-unadjusted mortality that was estimated for all pandemic periods combined (Figure 5C). However, the relative importance of these factors shifted as the pandemic progressed. 272 Early on, before widespread vaccination, pre-pandemic life expectancy was the strongest predictor of 273 excess deaths (Figure 5D). With the emergence of the Delta variant and increased vaccination rates, 274 vaccination coverage became the dominant factor, while the influence of life expectancy diminished 275 276 (Figure 5D). This shift underscores the critical role of vaccination in reducing excess mortality during 277 later stages of the pandemic, surpassing the impact of pre-existing health conditions. Notably, GDP 278 remained a significant factor throughout the pandemic, with its importance increasing after the Delta 279 variant's emergence.

However, for mortality that was estimated for all pandemic periods combined, and was adjusted for age, only vaccination coverage is a factor that is a significant contributor in a multivariable model, while life expectancy and GDP were not (Figure 5C).

Overall, the data emphasize the importance of vaccination in mitigating mortality but suggest that factors such as state-specific pre-pandemic life expectancy and economic status also play a role. Furthermore, the data show that age-adjusted and unadjusted excess mortality estimates are influenced by different parameters, though high vaccination rates minimize both.

287 **Discussion** 

# Age-adjusted and unadjusted excess mortality estimates: similarities, differences, and importance in evaluating pandemic impact

290 When comparing Figure 1A and Figure 1B, it is evident that the correlation between age-291 unadjusted pandemic excess mortality and state-specific life expectancy is stronger than the correlation with age-adjusted mortality. This stronger correlation can be attributed to the influence of population 292 293 age structure on both life expectancy and age-unadjusted pandemic excess mortality. The shared impact of population age structure explains the stronger correlation observed. Age-adjustment standardized the 294 mortality rates to a common age structure, allowing for a more accurate comparison between states 295 with different age demographics. Thus, unadjusted mortality that strongly correlates with life 296 expectancy paints a broad picture. Age-adjusted mortality provides a more nuanced view (23), 297 weakening the correlation but still showing a connection due to underlying factors impacting both 298 299 measures.

Examining both unadjusted and age-adjusted mortality paints a more nuanced picture of the pandemic's impact. Unadjusted mortality provides a raw count of lives lost, crucial for understanding the overall burden on each state. Age-adjusted mortality, however, helps us assess how effectively states managed the pandemic relative to their population's vulnerabilities. As Figure 1C illustrates, these mortality estimates are correlated, likely due to factors like healthcare access, poverty, and lifestyle choices. These factors can influence both mortality rates and life expectancy. If a state has poor

healthcare, we expect higher excess mortality rates and a lower life expectancy. So, even when adjusted for age structure, these underlying factors will still contribute to a connection between the two estimates. However, such underlying factors impacting both estimates are more pronounced in states with lower GDP. In contrast, states with higher GDP often have better healthcare systems and social safety nets, leading to lower mortality rates across all age groups.

It is not surprising that in the category of states with GDP below the certain threshold life expectancy correlates with state economic well-being as illustrated in Figure 1 D. For states with GDP exceeding \$65,000 per capita, the correlation between economic well-being and life expectancy weakens, suggesting limited additional life expectancy gains from further economic growth.

Our current study results related to US states align with a similar pattern observed in our previous analysis of European countries (11). This pattern reveals that the relative importance of GDP and vaccination rates in predicting age unadjusted excess mortality shifted with economic context. In countries or states with lower income levels, GDP played a more prominent role, compared to its role in countries or states with higher economic status. However, age-adjusted mortality correlates and therefore likely depends only on vaccination rates. The higher vaccination rates the lower mortality estimates.

Why do countries or states with lower economic capacity demonstrate higher age-unadjusted pandemic-associated fatalities, even if they have similarly high vaccination coverage as other countries or states? A plausible explanation for this phenomenon is that states with lower GDPs, compared to those with higher GDPs, had fewer effective measures to complement vaccination in preventing COVID-19 infections. The deficiency in these measures contributed to the higher mortality rates observed in these states.

#### 328 Vaccination rates strongly correlate with pre-pandemic life expectancy across US states.

Several contributing factors explain this correlation. Both metrics reflect a state's healthcare system capacity and its ability to adapt to crises. Additionally, strong public trust and a population willing to comply with public health measures play a role. Indeed, pre-pandemic life expectancy is highly and significantly inversely correlated with vaccination hesitancy estimated during the pandemic. This suggests a form of synergy between state governments and their residents. Effective government action to combat the pandemic is met with greater public cooperation, including low vaccine hesitancy that resulted in high vaccination uptake.

# Association between high vaccination coverage and excess mortality disappeared following the dominance of Omicron BA.1 virus variant.

Our analysis demonstrates a progressively stronger association between low vaccination rates 338 and high excess mortality that peaked during the Delta period. Eventually, death rates converge across 339 340 states in the post-Omicron BA.1 period, due to widespread seroconversion from natural infections. In the period following the dominance of Omicron BA.1, a considerable proportion of the population in 341 all states had already achieved immunity, which in states with low vaccination rates was offset by high 342 rates of natural infections. These infections resulted in excess deaths, but also contributed to a 343 strengthening of population immunity and this strengthening may have been substantial because of the 344 considerable number of infections that had occurred by the end of March 2022 in most states. Highly 345 likely that all states had achieved a comparable level of immunity by that point. 346

The findings from our analysis of both European countries and U.S. states offer insights for shaping strategies in future pandemics or infections surges of a lesser degree. Understanding the

patterns observed can inform proactive measures to mitigate the impact, particularly in regions with
 lower economic capacities.

#### 351 Conclusions

• States with lower life expectancy tend to have much higher pandemic-related deaths. 352 • Economic well-being (GDP) influences life expectancy, but with a potential threshold 353 effect. In this study the GDP threshold was defined as a value of \$65,000 per capita for 354 2020. Once a state achieves a certain level of economic well-being, its life expectancy does 355 not change significantly with further increases in GDP. 356 • Economic well-being (GDP) also plays a role in reducing excess mortality that is not 357 adjusted for age, but its importance varies depending on state income level. In states with 358 GDP per capita below the threshold, there's a stronger negative correlation between GDP 359 and mortality, while in remaining states, vaccination rates have a more prominent effect. 360 Vaccination rates play a most significant role in reducing excess mortality. This effect 361 is consistent across states regardless of income level. Notably, in multivariable regression 362 models, only vaccination rate, and not GDP remained as a significant factor affecting age-363

adjusted pandemic mortality. The category of front-runner states with the fastest vaccination
 campaigns that other states can model includes Vermont, Connecticut, Maine, Rhode Island,
 Massachusetts, New Jersey, Maryland, and New York.

Author Contributions: OM - data curation, formal analysis, research, writing, figures design; AO
 - statistical analysis, conceptualization; SS - conceptualization, statistical analysis, methodology,
 writing. All authors contributed to the article and approved the submitted version.

Funding: This work was funded by the Intramural Research Program of the National Library of
Medicine, National Institutes of Health (AYO and SAS).

372 Figure Legends

#### 373 Figure 1. Exploring relationships between state-specific pandemic mortality, life expectancy, and

GDP per capita Mortality calculated from January 1, 2020, to July 31, 2022. The Pearson correlation coefficients displayed above the scatterplots indicate statistically significant correlations (p < 0.05).

(A) Relationship of age-unadjusted pandemic mortality vs. state life expectancy. (B) Relationship of
age-adjusted pandemic mortality vs. state life expectancy. (C) Relationship of age-unadjusted vs. ageadjusted state specific mortalities. (D) Relationship of state life expectancy vs GDP.

Figure 2. Visualization of pandemic mortality waves/periods and vaccination rates (A) A timeline 379 of daily diagnosed COVID-19 deaths was created using the OWID database and presented along with 380 a scheme of the dominant virus variants causing infections. (B) States were categorized into three 381 groups based on their vaccination coverage in ascending order by October 2021. The "fast" category 382 (light blue background) consists of states that had achieved a vaccination rate of 60% for residents by 383 October 2021 and 70% by January 2022. The "slow" category (light pink background) includes states 384 in which more than half of the residents remained unvaccinated as of October 2021. The remaining 385 386 states are placed in the intermediate category (with a purple background). All states and Puerto Rico are shown in the order of the increasing percentage of the state population that had received the primary 387 series of the vaccine as of October 2, 2021. (C) Pandemic excess mortality not adjusted for age relative 388 to the state's population in different pandemic periods. 389

Figure 3. Excess mortality distributions in states categorised according to vaccination rates. States
 were categorized in the same manner as described in the legend of Figure 2, and each state's excess

mortality estimate (not adjuste for age) was plotted withing each category: (A) For the pre-Delta period,
which corresponds to the initial phase of vaccination. (B) For the Delta and Omicron BA.1 period,
representing an advanced stage of vaccination. (C) For the post-Omicron BA.1 period.

395 Figure 4. The distribution of GDPs per capita and life expectancy in states categorized as fast,

intermediate, and slow according to vaccination rate. States were categorized in the same manner
as described in the legend of Figure 2. GDP and life expectancy were estimated for each state within
each category and resuling estimates are presented as box-plots. Means with standard deviation are
shown for each category in the relevant box-plots. (A) The distribution od states according to GDP
per capita, (B) The distribution according to life expectancy at birth.

401 Figure 5. Regression analysis of pandemic excess mortality and key parameters that affected it

The top panels display results of univariable regression analysis as scatter plots. Pearson correlation 402 coefficients, indicating significant relationships (p < 0.05), are shown above the plots. Here, the 403 dependent variable is age-unadjusted excess mortality, with independent variables being: (A) Real GDP 404 405 per capita for 2020. (B) Vaccination rate, as the percentage of the population fully vaccinated with the primary series by October 2, 2021. The bottom panels present results of multivariable regression 406 analysis as vertical columns, reflecting negative log-transformed significance values of three key input 407 408 parameters. In all models, pandemic mortalities are the dependent variables, while and life expactancy, vaccination coverage, and annual GDP per capita are independent vcariables. For these models: (C) 409 410 Mortality for all pandemic periods combined, adjusted for age in model 1, and unadjusted for age in 411 model 2. (D) Age-unadjusted mortality for two pandemic periods: Model 4 represents the pre-Delta and pre-mass vaccination period of the pandemic, while Model 5 represents the Delta variant 412 dominance and mass vaccination period. 413

#### 414 Supplementary Figure 1. Relationships between state-specific pandemic mortality, and GDP per

**capita** Excess mortality was calculated as the percentage of normalized excess deaths for the state population from January 1, 2020, to July 31, 2022. The Pearson correlation coefficients displayed above the scatterplots indicate statistically significant correlations (p < 0.05). (A) Relationship of ageunadjusted pandemic mortality vs. GDP (B) Relationship of age-adjusted pandemic mortality vs. GDP. of age-unadjusted vs. age-adjusted state specific mortalities.

420 Supplementary Figure 2. Chronological Emergence of SARS-CoV-2 Dominant Variants in the
421 USA

Supplementary Figure 3. Correlation analysis of pandemic excess mortality for Delta and 422 **Omicron BA.1 periods separatly** Only statistically significant correlations (p < 0.05) are presented 423 above the corresponding scatter plots. Excess mortality that was not adjusted for age is depicted for: 424 (A) Delta period in relation to the annual actual GDP per capita in 2020. (B) Delta period in relation to 425 vaccination rates, expressed as a percentage of the state's fully vaccinated population as of October 2, 426 427 2021. (C) Omicron BA.1 period in relation to GDP per capita. (D) Omicron BA.1 period in relation to vaccination rates, calculated as a percentage of the state's fully vaccinated population as of January 2, 428 2022. (E) Omicron BA.1 period in relation to booster administration rates, calculated as a percentage 429 430 of the state's population that received an additional dose as part of the primary vaccine series as of January 2, 2022. 431

Supplementary Figure 4. Comparison of relationships of vaccination coverages with pandemic
excess mortality estimated with and without adjustement for age Both estimates were perforemd
for the period spanning from January 1, 2020, to July 31, 2023. State vaccination coverage was
estimated as October 2, 2021. Pearson correlation coefficients reflecting significant relationships (p <</li>

436 0.05) are shown above the scatter plots. (A) The dependent variable is excess mortality, not adjusted for
437 age. (B) The dependent variable is age-adjusted excess mortality.

### 438 **References**

1. Nie R, Abdelrahman Z, Liu Z, Wang X. Evaluation of the role of vaccination in the COVID-19

440 pandemic based on the data from the 50 U.S. States. Comput Struct Biotechnol J. 2022;20:4138-45.

441 2. Barro RJ. Vaccination rates and COVID outcomes across U.S. states. Econ Hum Biol.
442 2022;47:101201.

3. Bilinski A, Thompson K, Emanuel E. COVID-19 and Excess All-Cause Mortality in the US and

444 20 Comparison Countries, June 2021-March 2022. JAMA. 2023;329(1):92-4.

445 4. Du H, Saiyed S, Gardner LM. Association between vaccination rates and COVID-19 health
446 outcomes in the United States: a population-level statistical analysis. BMC Public Health.
447 2024;24(1):220.

Sah P, Vilches TN, Pandey A, Schneider EC, Moghadas SM, Galvani AP. Estimating the impact
of vaccination on reducing COVID-19 burden in the United States: December 2020 to March 2022. J
Glob Health. 2022;12:03062.

451 6. Shioda K, Chen Y, Collins MH, Lopman BA. Population-Level Relative Effectiveness of the

452 COVID-19 Vaccines and the Contribution of Naturally Acquired Immunity. J Infect Dis. 2022.

453 7. Suthar AB, Wang J, Seffren V, Wiegand RE, Griffing S, Zell E. Public health impact of covid-

454 19 vaccines in the US: observational study. BMJ. 2022;377:e069317.

8. Cuadros DF, Gutierrez JD, Moreno CM, Escobar S, Miller FD, Musuka G, et al. Impact of
healthcare capacity disparities on the COVID-19 vaccination coverage in the United States: A crosssectional study. Lancet Reg Health Am. 2023;18:100409.

Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. Assessing COVIDpandemic policies and behaviours and their economic and educational trade-offs across US states

460 from Jan 1, 2020, to July 31, 2022: an observational analysis. Lancet. 2023;401(10385):1341-60.

10. Basak P, Abir T, Al Mamun A, Zainol NR, Khanam M, Haque MR, et al. A Global Study on the
Correlates of Gross Domestic Product (GDP) and COVID-19 Vaccine Distribution. Vaccines.
2022;10(2):266.

464 11. Matveeva O, Shabalina S. Comparison of vaccination and booster rates and their impact on
465 excess mortality during the COVID-19 pandemic in European countries. Front Immunol. 2023;44.

12. Moradpour J, Shajarizadeh A, Carter J, Chit A, Grootendorst P. The impact of national income

and vaccine hesitancy on country-level COVID-19 vaccine uptake. PLoS One. 2023;18(11):e0293184.

468 13. Collaborators GBDD. Global age-sex-specific mortality, life expectancy, and population

estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of

the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease
Study 2021. Lancet. 2024;403(10440):1989-2056.

472 14. Andrasfay T, Goldman N. Reductions in US life expectancy during the COVID-19 pandemic
473 by race and ethnicity: Is 2021 a repetition of 2020? PLoS One. 2022;17(8):e0272973.

474 15. Centers for Disease Control and Prevention. National Center for Health Statistics. Life
475 Expectancy at Birth by State,
476 <u>https://www.cdc.gov/nchs/pressroom/sosmap/life\_expectancy/life\_expectancy.htm</u>, accessed March 9,
477 2024

478 16. National Center for Health Statistics. Excess Deaths Associated with COVID-19.
479 https://data.cdc.gov/d/xkkf-xrst, accessed July 18, 2023.

17. CensusBureau. Annual Estimates of the Resident Population for the United States, Regions, 480 States, District of Columbia, and Puerto Rico: April 1, 2020, to July 1, 2022 (NST-EST2022-POP), 481 Division, 482 Source: U.S. Census Bureau, Population Release Date: December 2022. https://www.census.gov/data/tables/time-series/demo/popest/2020s-state-total.html, accessed July 19, 483 2023. 484

- 485 18. US Centers for Disease Control and Prevention, Excess Deaths, Technical notes: accessed
  486 September 7, 2023. https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess deaths.htm#techNotes.
- 487 19. US Centers for Disease Control and Prevention, COVID-19 Vaccinations in the United States,
- 488 Jurisdiction, <u>https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-</u>
- 489 Jurisdi/unsk-b7fc, accessed November 16, 2023.
- 490 20. Bureau of Economic Analysis, Gross Domestic Product by State, 491 https://apps.bea.gov/regional/histdata/releases/0322gdpstate/index.cfm , accessed December 1, 2023.
- 492 21. Ruhter J. Office of Assistant Secretary for Planning and Evaluation (ASPE). Vaccine Hesitancy
- 493 for COVID-19: State, County, and Local Estimates: <u>https://aspe.hhs.gov/reports/vaccine-hesitancy-</u>
- 494 <u>covid-19-state-county-local-estimates</u>, accessed April 8, 2024.
- 495 22. MedCalc Software Ltd, Odds ratio calculator. <u>https://www.medcalc.org/calc/odds\_ratio.php</u>,
  496 accessed August 15, 2023.
- 497 23. Islam N, Jdanov DA. Age and sex adjustments are critical when comparing death rates. BMJ.
  498 2023;381:845.

# **Figures**

## Figure 1.



### Figure 2.











## Figure 5.



● U.S. states with a GDP per capita of \$65,000 or below 🗙 U.S. states with a GDP per capita above \$65,000 ○ USA as a country



## **Supplementary Figure 1.**



State GDP per capita

State GDP per capita

## **Supplementary Figure 2.**



SARS-CoV-2 sequences by variant, January 31, 2022

Alpha Beta Gamma Delta Omicron (BA.2) Omicron (BA.1) Omicron (BA.5) Omicron (BA.4) Omicron (BA.2.12.1) Omicron (BA.2.75) Omicron (BQ.1) Omicron (XBB.1.5) Omicron (XBB.1.16) Recombinant Others



SARS-CoV-2 sequences by variant, March 3, 2022

Alpha Beta Gamma Delta Omicron (BA2) Omicron (BA1) Omicron (BA5) Omicron ( Omicron (BA2121) Omicron (BA275) Omicron (BQ1) Omicron (XBB) Omicron (XBB.15) Omicron (XBB.10) Recombinant Others						
	Omi	cron BA.2 57%		Omicror 40%	n BA.1	
	2% 20	% 40	0% 60	0% 80	0% 10	00%

Our World in Data

100%

# **Supplementary Figure 3.**





## **Supplementary Figure 4.**





Vaccination coverage